GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DexTech Medical AB (XSAT:DEX) » Definitions » Investments And Advances

DexTech Medical AB (XSAT:DEX) Investments And Advances : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is DexTech Medical AB Investments And Advances?

DexTech Medical AB's Investments And Advances for the quarter that ended in Mar. 2025 was kr0.00 Mil.


DexTech Medical AB Investments And Advances Historical Data

The historical data trend for DexTech Medical AB's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexTech Medical AB Investments And Advances Chart

DexTech Medical AB Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DexTech Medical AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

DexTech Medical AB Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


DexTech Medical AB Business Description

Traded in Other Exchanges
N/A
Address
Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a well built clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.